Commentary on: A call for better reporting of trials using surrogate primary endpoints.
作者信息
Cummings Jeffrey
机构信息
Chambers-Gundy Center for Transformative Neuroscience Pam Quirk Brain Health and Biomarker Laboratory Department of Brain Health School of Integrated Health Sciences University of Nevada Las Vegas Las Vegas Nevada USA.
出版信息
Alzheimers Dement (N Y). 2022 Jul 26;8(1):e12339. doi: 10.1002/trc2.12339. eCollection 2022.
Abstract
摘要
相似文献
1
Commentary on: A call for better reporting of trials using surrogate primary endpoints.关于《呼吁更好地报告使用替代主要终点的试验》的评论
Alzheimers Dement (N Y). 2022 Jul 26;8(1):e12339. doi: 10.1002/trc2.12339. eCollection 2022.
2
A call for better reporting of trials using surrogate primary endpoints.呼吁更好地报告使用替代主要终点的试验。
Alzheimers Dement (N Y). 2022 Jul 26;8(1):e12340. doi: 10.1002/trc2.12340. eCollection 2022.
3
Endpoint selection and relative (versus absolute) risk reporting in published medication trials.已发表药物试验中终点选择和相对（相对于绝对）风险报告。
J Gen Intern Med. 2011 Nov;26(11):1246-52. doi: 10.1007/s11606-011-1813-7. Epub 2011 Aug 13.
4
A survey of endpoint characteristics in periodontal clinical trials published 1988-1992, and implications for future studies.1988 - 1992年发表的牙周临床试验终点特征调查及其对未来研究的启示。
J Clin Periodontol. 1995 May;22(5):397-407. doi: 10.1111/j.1600-051x.1995.tb00167.x.
5
Trends in Utilization of Surrogate Endpoints in Contemporary Cardiovascular Clinical Trials.当代心血管临床试验中替代终点的使用趋势
Am J Cardiol. 2016 Jun 1;117(11):1845-50. doi: 10.1016/j.amjcard.2016.03.021. Epub 2016 Mar 19.
6
Surrogate endpoints for overall survival in lung cancer trials: a review.肺癌试验中总生存期的替代终点：综述
Expert Rev Anticancer Ther. 2017 May;17(5):447-454. doi: 10.1080/14737140.2017.1316196. Epub 2017 Apr 12.
7
Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer.将肿瘤反应和无进展生存期联合作为晚期结直肠癌总生存期的替代终点。
Cancer Epidemiol. 2020 Feb;64:101665. doi: 10.1016/j.canep.2019.101665. Epub 2020 Jan 5.
8
Evaluation of Selective Outcome Reporting Bias in Efficacy Endpoints in Print and Television Advertisements for Oncology Drugs.评估肿瘤药物的印刷和电视广告中疗效终点的选择性结局报告偏倚。
J Gen Intern Med. 2020 Oct;35(10):2853-2857. doi: 10.1007/s11606-020-06028-1. Epub 2020 Jul 13.
9
10
Intermediate markers as surrogate endpoints in cancer research.癌症研究中作为替代终点的中间标志物。
Hematol Oncol Clin North Am. 2000 Aug;14(4):887-905. doi: 10.1016/s0889-8588(05)70317-8.
本文引用的文献
1
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
2
An Appropriate Use of Accelerated Approval - Aducanumab for Alzheimer's Disease.加速批准的合理应用——阿杜卡单抗用于阿尔茨海默病
N Engl J Med. 2021 Aug 26;385(9):856-857. doi: 10.1056/NEJMc2111960. Epub 2021 Jul 28.
3
Race and ethnicity reporting for clinical trials in ClinicalTrials.gov and publications.临床试验注册平台（ClinicalTrials.gov）和出版物中临床试验的种族和民族报告。
Contemp Clin Trials. 2021 Feb;101:106237. doi: 10.1016/j.cct.2020.106237. Epub 2020 Dec 5.
4
Five criteria for using a surrogate endpoint to predict treatment effect based on data from multiple previous trials.基于多个既往试验数据使用替代终点预测治疗效果的五条标准。
Stat Med. 2018 Apr 15;37(8):1406. doi: 10.1002/sim.7603. Epub 2018 Jan 22.
5
Biomarker definitions and their applications.生物标志物的定义及其应用。
Exp Biol Med (Maywood). 2018 Feb;243(3):213-221. doi: 10.1177/1535370217750088.
Zotero 插件